Britain’s Clinigen Group Plc has agreed to a sweetened takeover offer by UK-based private equity firm Triton, valuing the pharmaceutical services firm at about $1.78bn.
Shareholders in Clinigen, whose top investor is hedge fund Elliott, will receive 925 pence per share in cash, up from a December bid of 883 pence apiece.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
New York-based Elliott, which had been raising its holding in Clinigen over the past few months amid reports it was seeking a break-up of the group, owns a 10.5% stake in the British company, according to Refintiv Eikon data.
The latest offer by Triley Bidco, a newly created company indirectly owned by Triton Funds, is final and is recommended by the Clinigen board, the companies said in a joint statement.
Triton’s first offer made in December valued Clinigen, which provides healthcare professionals and their patients with access to medicines, at about 1.2 billion pounds.
Source: FX Empire
Can’t stop reading? Read more
UK private equity adapts as carried interest landscape begins to shift
UK private equity adapts as carried interest landscape begins to shift The number of UK private...
Blackstone strikes $6bn+ deal to acquire energy data firm Enverus
Blackstone strikes $6bn+ deal to acquire energy data firm Enverus Blackstone has agreed to acquire...
Uber seeks private equity backing to scale robotaxi ambitions
Uber seeks private equity backing to scale robotaxi ambitions Uber is in discussions with private...